Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications | 12 | 2023 | 2861 | 0.480 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2020 | 2408 | 0.470 |
Why?
|
| Depression, Postpartum | 4 | 2023 | 340 | 0.410 |
Why?
|
| Antidepressive Agents | 10 | 2020 | 2838 | 0.400 |
Why?
|
| Psychotropic Drugs | 4 | 2019 | 894 | 0.320 |
Why?
|
| Depressive Disorder | 8 | 2023 | 3748 | 0.300 |
Why?
|
| Depression | 6 | 2023 | 7766 | 0.290 |
Why?
|
| Psychotherapy | 3 | 2003 | 1643 | 0.250 |
Why?
|
| Bupropion | 1 | 2005 | 303 | 0.220 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2002 | 317 | 0.210 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2005 | 503 | 0.200 |
Why?
|
| Antimanic Agents | 2 | 2019 | 522 | 0.190 |
Why?
|
| Pregnancy | 14 | 2023 | 29144 | 0.160 |
Why?
|
| Mood Disorders | 2 | 2010 | 1106 | 0.150 |
Why?
|
| Drug Labeling | 1 | 2018 | 233 | 0.140 |
Why?
|
| Puerperal Disorders | 2 | 2000 | 275 | 0.140 |
Why?
|
| Antipsychotic Agents | 3 | 2019 | 3057 | 0.120 |
Why?
|
| Reproduction | 1 | 2018 | 668 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1584 | 0.090 |
Why?
|
| Perimenopause | 1 | 2011 | 139 | 0.090 |
Why?
|
| Risk | 3 | 2016 | 9687 | 0.090 |
Why?
|
| Bipolar Disorder | 3 | 2019 | 5027 | 0.090 |
Why?
|
| Influenza A virus | 1 | 1992 | 456 | 0.080 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2019 | 632 | 0.080 |
Why?
|
| Spleen | 1 | 1992 | 2362 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1992 | 1821 | 0.070 |
Why?
|
| Estradiol | 2 | 2011 | 2020 | 0.060 |
Why?
|
| Sudden Infant Death | 1 | 2007 | 291 | 0.060 |
Why?
|
| Postpartum Period | 1 | 2010 | 1086 | 0.060 |
Why?
|
| Affect | 1 | 2011 | 1476 | 0.060 |
Why?
|
| Female | 20 | 2023 | 380194 | 0.050 |
Why?
|
| Mianserin | 1 | 2001 | 52 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 1992 | 2725 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2011 | 6038 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2004 | 421 | 0.050 |
Why?
|
| Cyclohexanols | 1 | 2001 | 127 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2002 | 434 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2019 | 6600 | 0.040 |
Why?
|
| Humans | 20 | 2023 | 744343 | 0.040 |
Why?
|
| Recurrence | 4 | 2006 | 8340 | 0.040 |
Why?
|
| Depressive Disorder, Major | 2 | 2007 | 4644 | 0.040 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2019 | 80 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2005 | 1953 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2003 | 544 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2002 | 749 | 0.040 |
Why?
|
| Canada | 1 | 2023 | 2065 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 2795 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2019 | 456 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 1405 | 0.040 |
Why?
|
| Family Practice | 1 | 1999 | 516 | 0.040 |
Why?
|
| Lithium | 1 | 2000 | 601 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2001 | 745 | 0.030 |
Why?
|
| Postpartum Hemorrhage | 1 | 2019 | 258 | 0.030 |
Why?
|
| Sleep | 1 | 2011 | 4623 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2002 | 7279 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 10943 | 0.030 |
Why?
|
| Arsenicals | 1 | 1993 | 124 | 0.030 |
Why?
|
| Nucleoproteins | 1 | 1992 | 115 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2005 | 8324 | 0.030 |
Why?
|
| Adult | 10 | 2011 | 214055 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1990 | 42 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1992 | 1827 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1993 | 881 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1993 | 973 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 711 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2011 | 744 | 0.020 |
Why?
|
| Risk Assessment | 4 | 2010 | 23338 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 1993 | 1035 | 0.020 |
Why?
|
| Hot Flashes | 1 | 2011 | 317 | 0.020 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 15540 | 0.020 |
Why?
|
| Mass Screening | 1 | 2023 | 5255 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1992 | 986 | 0.020 |
Why?
|
| Risk Factors | 4 | 2004 | 72290 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2006 | 53288 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2007 | 25625 | 0.020 |
Why?
|
| Epitopes | 1 | 1993 | 2571 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1990 | 1369 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1992 | 1900 | 0.020 |
Why?
|
| Virus Replication | 1 | 1992 | 2534 | 0.010 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 2065 | 0.010 |
Why?
|
| Parity | 1 | 2007 | 929 | 0.010 |
Why?
|
| Psychotic Disorders | 1 | 2019 | 3046 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1993 | 13815 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1990 | 1607 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 1162 | 0.010 |
Why?
|
| Prevalence | 1 | 1999 | 15226 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 4258 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1993 | 18111 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 2001 | 37 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2006 | 599 | 0.010 |
Why?
|
| Causality | 1 | 2007 | 1275 | 0.010 |
Why?
|
| Pyridines | 1 | 2011 | 2825 | 0.010 |
Why?
|
| Cell Line | 1 | 1992 | 15997 | 0.010 |
Why?
|
| Middle Aged | 3 | 2011 | 213383 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2011 | 12026 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 85781 | 0.010 |
Why?
|
| Time Factors | 2 | 2010 | 40075 | 0.010 |
Why?
|
| Macrophages | 1 | 1990 | 5655 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2011 | 63114 | 0.010 |
Why?
|
| Menopause | 1 | 2001 | 1626 | 0.010 |
Why?
|
| Hemagglutinins, Viral | 1 | 1993 | 67 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 4933 | 0.010 |
Why?
|
| Age of Onset | 1 | 2000 | 3271 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1993 | 421 | 0.010 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1993 | 157 | 0.010 |
Why?
|
| Mice | 3 | 1993 | 81183 | 0.010 |
Why?
|
| Smoking | 1 | 2007 | 8987 | 0.010 |
Why?
|
| United States | 1 | 2018 | 69872 | 0.010 |
Why?
|
| Mycobacterium avium | 1 | 1990 | 28 | 0.010 |
Why?
|
| Toxoplasmosis, Animal | 1 | 1990 | 17 | 0.010 |
Why?
|
| Legionella | 1 | 1990 | 30 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1993 | 659 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2001 | 2690 | 0.010 |
Why?
|
| Arsenic | 1 | 1993 | 328 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 1993 | 541 | 0.010 |
Why?
|
| Listeriosis | 1 | 1990 | 149 | 0.010 |
Why?
|
| Toxoplasma | 1 | 1990 | 150 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1993 | 1266 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1990 | 156 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2004 | 13989 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1993 | 1475 | 0.000 |
Why?
|
| Chagas Disease | 1 | 1990 | 166 | 0.000 |
Why?
|
| Listeria monocytogenes | 1 | 1990 | 250 | 0.000 |
Why?
|
| Trypanosoma cruzi | 1 | 1990 | 198 | 0.000 |
Why?
|
| Male | 2 | 2018 | 350118 | 0.000 |
Why?
|
| Survival Analysis | 1 | 2000 | 10252 | 0.000 |
Why?
|
| Animals | 3 | 1993 | 168757 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 2007 | 77449 | 0.000 |
Why?
|
| Transfection | 1 | 1993 | 5892 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2007 | 40561 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1993 | 3772 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1993 | 6386 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 12797 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 4386 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 7301 | 0.000 |
Why?
|
Concepts
(135)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(15)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_